Processa Pharmaceuticals replaces auditor BD & Co. with Cherry Bekaert

Processa Pharmaceuticals, Inc.

BD & Co. resigned Oct 31, 2024 after merger into Citrin Cooperman; no disagreements or reportable events.
Audit Committee appointed Cherry Bekaert LLP for FY 2024 and subsequent interim periods.
No prior consultations with Cherry Bekaert regarding accounting principles or disagreements.
BD & Co.'s audit reports for 2023 and 2022 were unqualified and contained no adverse opinion.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.